The Stem Cell Networks Appoints Tamer Mohamed, CEO of Aspect Biosystems, to its Board of Directors
VANCOUVER, British Columbia - July 10, 2018 - Aspect Biosystems is pleased to announce the appointment of CEO Tamer Mohamed to the Stem Cell Network (SCN) Board of Directors, effective June 26, 2018. SCN's Board is comprised of 12 Canadian leaders, representing research, industry, healthcare and the not-for-profit sectors. Tamer is the most recent addition to the Board along with Dr. Julie Fradette, a professor and researcher at Université Laval.
“Julie and Tamer will bring new and important insights and expertise to our Board as we look forward to continuing our national leadership in translating stem cell and regenerative medicine from the lab to the clinic. I welcome them both and look forward to their contributions over the coming years,” said Dr. Michael Rudnicki, SCN’s Scientific Director.
“Regenerative medicine is about so much more than biology – it’s about designing integrated solutions across many disciplines to translate research into clinical and commercial applications. SCN is globally recognized for putting together the right teams and support to enable Canada to break new ground in this space, thereby ensuring we can compete in the global market. I look forward to working with SCN to continue this agenda,” said Mr. Mohamed.
This appointment follows Tamer's appointment to the Board of Directors at ACETECH earlier this year.
A full list of SCN’s Board members, with biographies, can be found at: https://stemcellnetwork.ca/about-us/governance/
About Aspect Biosystems
Aspect Biosystems Ltd. is a privately held biotechnology company operating at the leading edge of 3D bioprinting and tissue engineering. The company’s proprietary Lab-on-a-Printer™ platform technology is enabling advances in understanding fundamental biology, disease research, development of novel therapeutics, and regenerative medicine. In addition to its internal tissue development programs, Aspect is focused on strategically partnering with pharmaceutical and biotechnology companies, as well as academic researchers, to create physiologically and commercially relevant tissues. These tissues are used for impactful applications in therapeutic discovery and regenerative medicine. www.aspectbiosystems.com
About the Stem Cell Network
Building Canada’s stem cell and regenerative medicine research sector has been the raison d’être of the Stem Cell Network (SCN) since its inception in 2001. In just over 17 years, SCN has forged a national community that has transformed stem cell research in Canada, brought research to the point where regenerative medicine is changing clinical practice and established an outstanding international reputation. SCN has pushed the boundaries of what was a basic research area towards translational outcomes for the clinic and marketplace. By the end of 2017, SCN had provided more than $100 million for innovative translational research. This funding has benefitted 169 world-class research groups and more than 2,500 trainees from across Canada. SCN has catalyzed 18 clinical trials and 16 regenerative medicine start-up companies. SCN investigators have leveraged upwards of $100 million in partner contributions while SCN has incubated several international and Canadian research networks and organizations. www.stemcellnetwork.ca
Interim Communications Director
Stem Cell Network